Medicago reports promising early Phase 1 test results of possible COVID-19 vaccine

Quebec City-based Medicago says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.

The Canadian Press

QUEBEC — Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.

The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.

Medicago says the side effects were generally mild to moderate and short in duration.

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

The federal government has signed a $173-million contract with Medicago to secure the rights to buy 76 million doses of its vaccine, should it meet health and safety standards.

Medicago reports promising early Phase 1 test results of possible COVID-19 vaccine

Related stories

Singh demands Afghan interpreters' families be allowed into Canada as Taliban surges

Indigenous lobster fishing boats cut loose from wharf in Nova Scotia: First Nation

Ottawa won't share details on Afghan refugees due to security reasons: Mendicino

Take action

Make a donation